HOW EFFECTIVE? In a study conducted on 15 thousand people in the UK, it was revealed that the Novavax vaccine was 89 percent effective in preventing Covid-19. In clinical trials in which more than 15 thousand people between the ages of 18-84 participated, 27 percent of whom were over the age of 65, it was stated that the vaccine provided 100 percent protection against serious diseases, including hospitalization and death. Based on the Phase 3…"The last fighter of the pandemic: Novavax Covid-19 vaccine is expected to be approved soon – Health News"
Ylva Johansson, Commissioner for Internal Affairs of the European Union (EU) Commission, said in Brussels on Friday that the EU’s planned vaccine identification will only document vaccines that have been approved by the European Medicines Agency (EMA). This statement means that those who use Russian and Chinese vaccines intended to be used in some European countries will not be given a vaccine ID. In addition to the vaccine developed by EMA in partnership with Biontech…"The EU’s vaccine identity is only for approved vaccines."